BigHat Biosciences
BETTER BIOLOGICS FASTER THROUGH AI-GUIDED DESIGN

BigHat Biosciences is designing safer, more effective antibody therapies for patients using machine learning and synthetic biology.

BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies.

We are applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
 
BigHat operates out of San Mateo, CA, in the San Francisco Bay Area. We pride ourselves on our team-oriented, inclusive, remote-friendly, and family-centric culture.

Investors

BigHat Biosciences is supported by world-class investors including those listed below and others. The company closed a $75 million Series B in July 2022, $19 million Series A in January 2021, and $5 million Seed in October 2019.